Published in Thromb Res on November 01, 2000
Evaluation of plasma levels of tumour necrosis factor alpha and interleukin-6 as rejection markers in a cohort of 142 heart-grafted patients followed by endomyocardial biopsy. Eur Heart J (1997) 1.53
Aortic valve homografts in the surgical treatment of complex cardiac malformations. J Thorac Cardiovasc Surg (1984) 0.91
[Thrombolytic action of heparin and a low molecular weight fraction]. Therapie (1985) 0.88
What is the effect of acetylsalicylic acid at ultra low dose on the interaction platelets/vessel wall? Thromb Res (1990) 0.85
Chronic progressive external ophthalmoplegia: a new heteroplasmic tRNA(Leu(CUN)) mutation of mitochondrial DNA. J Neurol Sci (2008) 0.85
Thromboembolic complications several days after a single-dose administration of aspirin. Thromb Res (1998) 0.84
Effects of aspirin on embolization in an arterial model of laser-induced thrombus formation. Haemostasis (1993) 0.83
Importance of photo activation of rose bengal for platelet activation in experimental models of photochemically induced thrombosis. Thromb Res (1996) 0.83
Experimental thrombosis model induced by laser beam. Application of aspirin and an extract of Ginkgo biloba: EGb 761. Thromb Res (1996) 0.82
Experimental thrombosis model induced by free radicals. Application to aspirin and other different substances. Thromb Res (1995) 0.82
Combination of two doses of acetyl salicylic acid: experimental study of arterial thrombosis. Thromb Res (1998) 0.81
What is the best plasmatic activity which could be correlated with the antithrombotic effect of heparin and a low molecular weight heparin fragment? Thromb Res (1987) 0.80
Effect of the low molecular weight heparin/non steroidal anti-inflammatory drugs association on an experimental thrombosis induced by laser. Thromb Res (1995) 0.80
New class of heparin derivatives with a potent antithrombotic effect and a very limited hemorrhagic activity. Thromb Res (1996) 0.80
Action of neurotransmitters: acetylcholine, serotonin, and adrenaline in an experimental arterial thrombosis induced by oxygen free radicals. Thromb Res (1997) 0.79
2006 GEP-ISFG collaborative exercise on mtDNA: reflections about interpretation, artefacts, and DNA mixtures. Forensic Sci Int Genet (2007) 0.79
Thrombogenic properties of ultra-low-dose of acetylsalicylic acid in a vessel model of laser-induced thrombus formation. Thromb Res (1994) 0.79
Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis. Thromb Res (1983) 0.78
Localization of the structural domain responsible for the chemotactic properties of thrombin on polymorphonuclear leukocytes. Thromb Res (1990) 0.78
Vasoconstrictive response of rat mesenteric arterioles following infusion of cross-linked, polymerized, and conjugated hemoglobin solutions. Artif Cells Blood Substit Immobil Biotechnol (2001) 0.78
In vitro platelets/endothelial cells interactions in presence of acetylsalicylic acid at various dosages. Thromb Res (1992) 0.78
[Antithrombotic effect of piavit--a substance from the medicinal leech (Hirudo medicinalis), containing prostanoid and destabilase fractions]. Biokhimiia (1995) 0.77
Time related neutralization of two doses acetyl salicylic acid. Thromb Res (2000) 0.77
Virus inactivation of fresh frozen plasma by a solvent detergent procedure: biological results. Vox Sang (1992) 0.77
Some hemostatic and hemorheological disorders in auditory and vestibular impairments. Thromb Res (1992) 0.77
Effects of aprotinin on heparin activities and heparin neutralization with protamine. Thromb Res (1992) 0.77
Coagulation impact on chemotactic activity generation for polymorphonuclear leukocytes. Thromb Res (1990) 0.77
Increase of arterial thrombosis parameters in chronic Helicobacter pylori infection in mice. Thromb Res (2002) 0.76
Could non steroidal anti-inflammatory drugs be used to potentiate L.M.W.H activity in thrombosis? (Part I). Thromb Res (1991) 0.76
Beneficial effect of ultra-low-dose aspirin in platelet activity alterations and haemorrhage observed in experimental portal hypertension. Thrombosis (2011) 0.75
Effects of external electrical stimulation on laser-beam-induced experimental thrombosis. Pathophysiol Haemost Thromb (2006) 0.75
[Interactions between blood and biomaterials. Applications to extracorporeal circulation]. Pathol Biol (Paris) (1982) 0.75
[Free radicals and thrombosis]. Ann Cardiol Angeiol (Paris) (1995) 0.75
Role of bone marrow in the development of thrombosis. A study of the curative and prophylactic action of heparin and heparin fragment (CY 222). Thromb Res (1989) 0.75
[Antithrombotic agents]. Ann Cardiol Angeiol (Paris) (1993) 0.75
Kinetic study of tPA release induced by heparin and heparin fragment. Thromb Res (1989) 0.75
[Potentiation by heparins of the action of leukocytes in experimental venous thrombosis]. Ann Pharm Fr (1988) 0.75
[Presence of radioactivity in the gastric juice of dogs after the intracardiac injection of 3H-or 35S-labeled heparin]. C R Seances Acad Sci III (1983) 0.75
Haemostasis defects following cardio-pulmonary by-pass based on a study of 1350 patients. Thromb Haemost (1978) 0.75
[Action of onion, Allium cepa L., on primary hemostasis in healthy volunteers before and after absorption of a high-fat meal]. Ann Pharm Fr (1985) 0.75
[Experimental models of arterial thrombosis]. Ann Cardiol Angeiol (Paris) (1995) 0.75
[Experimental models of venous thrombosis]. Ann Cardiol Angeiol (Paris) (1995) 0.75
Arterial antithrombotic effect of piyavit, the novel pharmacological preparation from the medicinal leech, and of its components, prostanoids and enzyme destabilase. Thromb Res (1995) 0.75
[Low molecular weight heparins]. Ann Pharm Fr (1989) 0.75
Detection and prevention of a fibrinolysis after an extra-corporeal circulation in cardiac surgery. Thromb Haemost (1976) 0.75
[Role of the indirect fibrinolytic activity of heparins and similar compounds in the prevention of thrombosis]. Ann Pharm Fr (1983) 0.75
Action of neurotransmitters: acetylcholine, adrenaline and serotonin on arterial thrombosis induced by a laser beam. Thromb Res (1996) 0.75
Aspirin fails to prevent experimental arterial thrombosis induced by oxygen free radicals. Thromb Res (1996) 0.75
[Are contrast agents prothrombotic?]. Ann Cardiol Angeiol (Paris) (1995) 0.75
Effect of monoclonal and polyclonal antibodies against conjugated neurotransmitter on experimental venous thrombosis. Semin Thromb Hemost (1996) 0.75
Fibrinogen as a factor of thrombosis: experimental study. Thromb Res (1998) 0.75
Laboratory control of heparin and heparin fragment treatment: an experimental study. Semin Thromb Hemost (1989) 0.75
[Hemostasis]. Rev Laryngol Otol Rhinol (Bord) (1979) 0.75
[Action of prostacyclin on the extension of experimental venous thrombosis]. Ann Pharm Fr (1984) 0.75
Is there an optimal therapeutical range for low molecular weight heparin? An experimental study. Thromb Res (1988) 0.75
[How to standardize low molecular weight heparins]. Ann Biol Clin (Paris) (1990) 0.75
Antithrombotic effects of aspirin and LMWH in a laser-induced model of arterials and venous thrombosis. Thromb Res (1996) 0.75
Influence of heparin and a low molecular weight heparin fraction of the leukocytes in an experimental venous thrombosis model. J Leukoc Biol (1987) 0.75
[Biological study of Meniere's disease and Meniere's syndrome: preliminary note]. Rev Laryngol Otol Rhinol (Bord) (1975) 0.75
[Biochemistry of the fluids of the inner ear]. Rev Laryngol Otol Rhinol (Bord) (1976) 0.75
[Variations in hemostasis in the infant under deep hypothermia]. Ann Anesthesiol Fr (1977) 0.75
Experimental venous thrombosis in rats treated with heparin and a low molecular weight heparin fraction. Haemostasis (1983) 0.75
The role of essential vitamins in the development of thrombosis and hemorrhage--an experimental study. Thromb Res (1992) 0.75
[Action of aspartate on the blood lactic acid of patients in the post-aggressive phase]. Agressologie (1973) 0.75
[Passage of commercial heparin and a low molecular weight fragment of heparin, CY 222, across the placenta of pregnant rabbits]. Pathol Biol (Paris) (1985) 0.75
[Oral administration of heparin and low molecular weight heparin fractions in rabbits]. Therapie (1984) 0.75
[Low-molecular weight heparins in post-surgical recovery]. Ann Biol Clin (Paris) (1988) 0.75
Aspirin and fraxiparine in the prevention of laser induced thrombosis in the presence of iodinated contrast media. Thromb Res (1998) 0.75
The arterial antithrombotic activity of thioxylosides in a rat model of laser-induced thrombosis. Semin Thromb Hemost (1996) 0.75
Thrombogenicity of ionic and nonionic contrast media tested in a laser induced rat thrombosis model. Thromb Res (1995) 0.75
[Heparin and chemically related compounds. Study in experimental thrombosis]. Ann Pharm Fr (1983) 0.75
Prevention of laser arterial thrombus formation with unfractionated heparin. Haemostasis (1994) 0.75
The tPA-like activity induced by heparin and a heparin fragment binds on experimental thrombus. Thromb Res (1988) 0.75
[Further data on the study of Menière's disease and menieriform syndromes]. Rev Laryngol Otol Rhinol (Bord) (1975) 0.75
Modifications of biological activities of heparin and fraxiparine induced by the size and the age of a thrombus. Experimental study. Thromb Res (1990) 0.75
Effects of acetyl salicylic acid therapy on an experimental thrombosis induced by laser beam. Thromb Res (2000) 0.75
Influence of heparin on the chemotactic activity of human thrombin. J Pharm Pharmacol (1993) 0.75
Could thrombus age be a modulator of heparin or L.M.W.H. activities? Thromb Res (1989) 0.75
Comparative study of three recombinant hirudins with heparin in an experimental venous thrombosis model. Haemostasis (1991) 0.75
[Hemorheological problems and alterations in erythrocyte filterability in vascular diseases]. Acta Med Port (1983) 0.75